Bionor Immuno AS
Latest by Bionor Immuno AS
New Path to Therapeutic HIV Vaccine Discovered by Studying Immunologic Profile of Rare HIV Controllers
Oslo -- Based on encouraging results from pre-clinical research, Bionor Immuno AS, today announced intentions to take the therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5 into a Phase I/II clinical trial. The research results in...